Elucidating Mechanisms For The Biological Activities Of CD46.
Funder
National Health and Medical Research Council
Funding Amount
$228,000.00
Summary
The CD46 protein enables entry into cells of a number of different pathogens, including the measles virus, Neisseria meningitidis (the major cause of meningococcal disease), Neisseria gonorrhoea, Human Herpes Virus 6, and group A streptococcus. In addition, by binding to a key blood component that is often attached to foreign pathogens, CD46 can facilitate binding and entry of other pathogens. As well as facilitating entry of the pathogen, it has recently become apparent that CD46 binding trigge ....The CD46 protein enables entry into cells of a number of different pathogens, including the measles virus, Neisseria meningitidis (the major cause of meningococcal disease), Neisseria gonorrhoea, Human Herpes Virus 6, and group A streptococcus. In addition, by binding to a key blood component that is often attached to foreign pathogens, CD46 can facilitate binding and entry of other pathogens. As well as facilitating entry of the pathogen, it has recently become apparent that CD46 binding triggers a wide range of responses from the human host. Some of these responses are likely to further facilitate survival and proliferation of the pathogen, but others are more likely to facilitate host defence. For examples, signals triggered by binding to CD46 can both abrogate some aspects of the immune response (and it is though that this immunosuppression contributes to the secondary infections that cause the death of nearly one million children each year) and facilitate other aspects of the immune response. By understanding the mechanisms by which CD46 triggers these complex responses, we firstly be able to dissect how important each of these processes are to the overall pathogenecity of the virus or bacteria. Furthmore, this understanding will allow us to design better vaccines and drugs to combat these diseases.Read moreRead less
Development Of Improved Vaccine Strategies For Measles Using Plant-derived Edible Vaccines
Funder
National Health and Medical Research Council
Funding Amount
$331,980.00
Summary
Measles is a highly contagious viral disease that is contracted via the respiratory tract. Severe infection may lead to complications such as otitis media, pneumonia, encephalitis. Despite our current vaccination strategy outbreaks still occur in Australia and measles is a major problem in developing countries. In developing nations the case fatality rate of measles is several hundred times that of developed nations. Over 800,000 children still die each year due to measles. Problems with the cur ....Measles is a highly contagious viral disease that is contracted via the respiratory tract. Severe infection may lead to complications such as otitis media, pneumonia, encephalitis. Despite our current vaccination strategy outbreaks still occur in Australia and measles is a major problem in developing countries. In developing nations the case fatality rate of measles is several hundred times that of developed nations. Over 800,000 children still die each year due to measles. Problems with the current vaccination strategy are: a) doesn't work in children less than 1 year of age, b) must be kept cold c) must be given by injection. We believe that a plant derived edible vaccine for measles will address the limitations of currently available vaccine i.e. we can give it children under the age of 1 year, it can be eaten and doesn't have to be kept cold.Read moreRead less
Understanding The Host Pathogen Relationships Of Hendra Virus In Bats, Horses And Humans
Funder
National Health and Medical Research Council
Funding Amount
$648,339.00
Summary
We will examine why bats can be infected with Hendra Virus with no apparent symptoms, yet the virus causes severe disease in other mammals including humans. We will examine the innate immune response towards the virus in the natural host (fruit bats), horses and humans. In addition to the innate immune response we will also examine the adaptive immune response in bats and humans. We hope this information can be used to design new drugs or vaccines to Hendra Virus.
A vaccine to prevent AIDS is urgently needed. The European Union recently awarded over 20 million euros to a European consortium, called EAVI2020, to advance multiple HIV vaccines into human testing. Five Australian HIV vaccine experts are named investigators on this award to provide advanced laboratory analyses and intellectual input into the 5 year program if this NHMRC-EU Collaborative Research Grant is successful.